Overall EGRX gets a fundamental rating of 4 out of 10. We evaluated EGRX against 525 industry peers in the Biotechnology industry. EGRX has a medium profitability rating, but doesn't score so well on its financial health evaluation. EGRX is valued correctly, but it does not seem to be growing.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year EGRX was profitable.
EGRX had a negative operating cash flow in the past year.

1.2 Ratios

EGRX's Return On Assets of 2.99% is amongst the best of the industry. EGRX outperforms 94.01% of its industry peers.
The Return On Equity of EGRX (4.80%) is better than 94.54% of its industry peers.
The Return On Invested Capital of EGRX (10.53%) is better than 95.77% of its industry peers.
EGRX had an Average Return On Invested Capital over the past 3 years of 13.59%. This is below the industry average of 18.07%.

		Industry Rank	Sector Rank
ROA	2.99%
ROE	4.8%
ROIC	10.53%

ROA(3y)3.37%

ROA(5y)5.82%

ROE(3y)5.61%

ROE(5y)8.93%

ROIC(3y)13.59%

ROIC(5y)13.5%

1.3 Margins

EGRX has a better Profit Margin (4.70%) than 94.19% of its industry peers.
EGRX's Profit Margin has declined in the last couple of years.
EGRX's Operating Margin of 16.47% is amongst the best of the industry. EGRX outperforms 95.77% of its industry peers.
In the last couple of years the Operating Margin of EGRX has declined.
EGRX has a better Gross Margin (69.86%) than 84.33% of its industry peers.
EGRX's Gross Margin has declined in the last couple of years.

		Industry Rank	Sector Rank
OM	16.47%
PM (TTM)	4.7%
GM	69.86%

OM growth 3Y42.71%

OM growth 5Y-1.58%

PM growth 3Y15.49%

PM growth 5Y-12.5%

GM growth 3Y0.54%

GM growth 5Y-1.58%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EGRX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for EGRX has been increased compared to 1 year ago.
EGRX has a worse debt/assets ratio than last year.

2.2 Solvency

EGRX has an Altman-Z score of 1.81. This is not the best score and indicates that EGRX is in the grey zone with still only limited risk for bankruptcy at the moment.
EGRX has a Altman-Z score of 1.81. This is in the better half of the industry: EGRX outperforms 70.07% of its industry peers.
A Debt/Equity ratio of 0.25 indicates that EGRX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.25, EGRX is doing worse than 68.84% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.25
Debt/FCF	N/A
Altman-Z	1.81

ROIC/WACC1.32

WACC7.97%

2.3 Liquidity

A Current Ratio of 2.16 indicates that EGRX has no problem at all paying its short term obligations.
EGRX has a Current ratio of 2.16. This is in the lower half of the industry: EGRX underperforms 75.35% of its industry peers.
EGRX has a Quick Ratio of 1.67. This is a normal value and indicates that EGRX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.67, EGRX is doing worse than 79.58% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.16
Quick Ratio	1.67

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for EGRX have decreased strongly by -33.52% in the last year.
EGRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.81% yearly.
The Revenue has decreased by -5.40% in the past year.
Measured over the past years, EGRX shows a small growth in Revenue. The Revenue has been growing by 5.99% on average per year.

EPS 1Y (TTM)-33.52%

EPS 3Y44.53%

EPS 5Y14.81%

EPS Q2Q%-24.36%

Revenue 1Y (TTM)-5.4%

Revenue growth 3Y17.35%

Revenue growth 5Y5.99%

Sales Q2Q%-12.76%

3.2 Future

EGRX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -11.47% yearly.
The Revenue is expected to grow by 0.24% on average over the next years.

EPS Next Y-40.26%

EPS Next 2Y-34.69%

EPS Next 3Y-26.94%

EPS Next 5Y-11.47%

Revenue Next Year-19.31%

Revenue Next 2Y-18.72%

Revenue Next 3Y-11.22%

Revenue Next 5Y0.24%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 0.46, which indicates a rather cheap valuation of EGRX.
EGRX's Price/Earnings ratio is rather cheap when compared to the industry. EGRX is cheaper than 99.82% of the companies in the same industry.
EGRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.60.
With a Price/Forward Earnings ratio of 0.64, the valuation of EGRX can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EGRX indicates a rather cheap valuation: EGRX is cheaper than 99.65% of the companies listed in the same industry.
EGRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.83.

		Industry Rank	Sector Rank
PE	0.46
Fwd PE	0.64

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EGRX is valued cheaply inside the industry as 99.12% of the companies are valued more expensively.